Employees Retirement System of Texas trimmed its holdings in shares of Glaukos Corporation (NYSE:GKOS) by 8.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 79,000 shares of the medical instruments supplier’s stock after selling 7,000 shares during the period. Employees Retirement System of Texas owned about 0.23% of Glaukos Corporation worth $3,276,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Great West Life Assurance Co. Can bought a new position in shares of Glaukos Corporation during the first quarter valued at about $102,000. Comerica Bank bought a new position in shares of Glaukos Corporation during the first quarter valued at about $1,562,000. Parametric Portfolio Associates LLC raised its stake in Glaukos Corporation by 39.1% in the first quarter. Parametric Portfolio Associates LLC now owns 61,561 shares of the medical instruments supplier’s stock worth $3,158,000 after buying an additional 17,313 shares in the last quarter. Prudential Financial Inc. bought a new position in Glaukos Corporation in the first quarter worth about $204,000. Finally, American International Group Inc. raised its stake in Glaukos Corporation by 7.1% in the first quarter. American International Group Inc. now owns 10,293 shares of the medical instruments supplier’s stock worth $528,000 after buying an additional 681 shares in the last quarter. Institutional investors and hedge funds own 88.95% of the company’s stock.
Shares of Glaukos Corporation (NYSE GKOS) opened at 32.60 on Wednesday. Glaukos Corporation has a one year low of $28.72 and a one year high of $52.49. The company has a 50-day moving average of $33.87 and a 200 day moving average of $33.87. The stock’s market cap is $1.12 billion.
A number of equities analysts recently issued reports on GKOS shares. BidaskClub raised shares of Glaukos Corporation from a “hold” rating to a “buy” rating in a research note on Saturday, June 24th. Zacks Investment Research raised shares of Glaukos Corporation from a “hold” rating to a “strong-buy” rating and set a $48.00 price target for the company in a research note on Tuesday, July 4th. Roth Capital decreased their target price on shares of Glaukos Corporation from $60.00 to $54.00 and set a “buy” rating for the company in a research note on Thursday, August 3rd. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $56.00 target price on shares of Glaukos Corporation in a research note on Thursday, August 3rd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $48.57.
ILLEGAL ACTIVITY NOTICE: This report was first posted by BBNS and is the property of of BBNS. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://baseballnewssource.com/markets/employees-retirement-system-of-texas-has-3-28-million-position-in-glaukos-corporation-gkos/1701513.html.
In related news, CEO Thomas William Burns sold 1,212 shares of the business’s stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $41.25, for a total value of $49,995.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Orbimed Advisors Llc sold 325,000 shares of the business’s stock in a transaction dated Thursday, August 17th. The stock was sold at an average price of $37.93, for a total transaction of $12,327,250.00. The disclosure for this sale can be found here. Insiders have sold a total of 980,200 shares of company stock worth $37,900,263 over the last 90 days. Insiders own 16.40% of the company’s stock.
About Glaukos Corporation
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with our FREE daily email newsletter.